ENOXACIN

US Previously Marketed

First approved in 1991

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H17FN4O3
Molecular Weight	320.3189
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN1C=C(C(O)=O)C(=O)C2=C1N=C(N3CCNCC3)C(F)=C2

InChI

InChIKey=IDYZIJYBMGIQMJ-UHFFFAOYSA-N

InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)

HIDE SMILES / InChI

Molecular Formula	C15H17FN4O3
Molecular Weight	320.3189
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6226242 | https://www.ncbi.nlm.nih.gov/pubmed/8429114 | https://www.ncbi.nlm.nih.gov/pubmed/8494374

Enoxacin is an oral broad-spectrum fluoroquinolone antibacterial agent used in the treatment of urinary tract infections and gonorrhea. Enoxacin is bactericidal drugs, eradicating bacteria by interfering with DNA replication. Like other fluoroquinolones, enoxacin functions by inhibiting bacterial DNA gyrase and topoisomerase IV. The inhibition of these enzymes prevents bacterial DNA replication, transcription, repair and recombination. Enoxacin is active against many Gram-positive bacteria. After oral administration enoxacin is rapidly and well absorbed from the gastrointestinal tract. The antibiotic is widely distributed throughout the body and in the different biological tissues. Tissue concentrations often exceed serum concentrations. The binding of enoxacin to serum proteins is 35 to 40%. The serum elimination half-life, in subjects with normal renal function, is approximately 6 hours. Approximately 60% of an orally administered dose is excreted in the urine as unchanged drug within 24 hours. Enoxacin, like other fluoroquinolones, is known to trigger seizures or lower the seizure threshold. The compound should not be administered to patients with epilepsy or a personal history of previous convulsive attacks as may promote the onset of these disorders.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Topoisomerase IV 62 Target ID: CHEMBL2363077 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18813225	Inhibitor 8504
Bacterial DNA gyrase 66 Target ID: CHEMBL2311224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9341164	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. 3 Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm	Curative	Approved 8583	PENETREX Approved Use INDICATIONS AND USAGE. Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis*, or Staphylococcus saprophyticus. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae. Launch Date 1991
Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis, or Staphylococcus saprophyticus 3 Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm	Curative	Approved 8583	PENETREX Approved Use INDICATIONS AND USAGE. Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis*, or Staphylococcus saprophyticus. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae. Launch Date 1991
Complicated urinary tract infections 12 Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm	Curative	Approved 8583	PENETREX Approved Use INDICATIONS AND USAGE. Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis*, or Staphylococcus saprophyticus. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae. Launch Date 1991

C_max

Value	Dose	Analyte	Population
1.83 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.58 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, intravenous dose: 800 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.02 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.7 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	4-OXO-ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	4-OXO-ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
5.35 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
29.08 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, intravenous dose: 800 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.67 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
25.75 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, intravenous dose: 800 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	4-OXO-ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Doses

Dose	Population	Adverse events
600 mg single, oral Highest studied dose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	unhealthy, 41.9 years Health Status: unhealthy Age Group: 41.9 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	unhealthy, 43.8 years Health Status: unhealthy Age Group: 43.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/
600 mg 3 times / day multiple, oral Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	Other AEs: Gastrointestinal disorders, Epidermal and dermal conditions... Other AEs: Gastrointestinal disorders (1.3%) Epidermal and dermal conditions (0.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/

AEs

AE	Significance	Dose	Population
Epidermal and dermal conditions	0.4%	600 mg 3 times / day multiple, oral Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/
Gastrointestinal disorders	1.3%	600 mg 3 times / day multiple, oral Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 P-gp 1741	MATE1 182 OATP1A2 67	CYP1A2 832 CYP2B1 26 CYP2B2 15 CYP2E1 131 CYP3A1 4 CYP3A2 6 CYP4A1 17 CYP1A1 151

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A1 272	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP2B1 41	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP2B2 16	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP2E1 1146	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP3A1 5	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP3A2 13	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP4A1 25	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15543082/	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/8347124/;https://pubmed.ncbi.nlm.nih.gov/10096258/	yes [Inhibition 250 uM]	yes (co-administration study) Comment: enoxacin caused a 6-fold decrease in caffeine clearance Sources: https://pubmed.ncbi.nlm.nih.gov/8347124/;https://pubmed.ncbi.nlm.nih.gov/10096258/
CYP1A2 2333	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
MATE1 182	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19004926/	yes
OATP1A2 67	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565919/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:157175	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:157175
ChemicalBook	CB2403021	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2403021
eMolecules	538022	https://www.emolecules.com/cgi-bin/more?vid=538022
MolPort	MolPort-003-666-456	https://www.molport.com/shop/molecule-link/MolPort-003-666-456
Selleck Chemicals	Enoxacin(Penetrex)	http://www.selleckchem.com/products/Enoxacin(Penetrex).html
ZINC	ZINC000019594549	http://zinc15.docking.org/substances/ZINC000019594549

PubMed

Title	Date	PubMed
Induction of keratinocyte apoptosis by photosensitizing chemicals plus UVA.	2007-02	17141480
A new approach to quantitative NMR: fluoroquinolones analysis by evaluating the chemical shift displacements.	2006-10-11	16765011
Quinolones for uncomplicated acute cystitis in women.	2006-07-19	16856014
A batch chemiluminescence determination of enoxacin using a tris-(1,10-phenanthroline)ruthenium(II)-cerium(IV) system.	2006-07	16794867
Electrochemiluminescence of terbium (III)-two fluoroquinolones-sodium sulfite system in aqueous solution.	2006-05-01	16098798
Simultaneous determination of (fluoro)quinolone antibiotics in kidney, marine products, eggs, and muscle by enzyme-linked immunosorbent assay (ELISA).	2006-04-19	16608195
Effect of fluoroquinolones on plasma glucose levels in fasted and glucose-loaded mice.	2006-04	16648952
Mutagenesis induced by 12 quinolone antibacterial agents in Escherichia coli WP2uvrA/pKM101.	2006-04	16171969
[Study on interaction of caffeine and theophylline with bovine serum albumins].	2006-03	16830766
Genotoxic potential of quinolone antimicrobials in the in vitro comet assay and micronucleus test.	2006-02-28	16384725
Antimicrobial drug resistance, regulation, and research.	2006-02	16494740
Radiation-induced in vitro phototoxic potential of some fluoroquinolones.	2006-01	16455588
Effects of Transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes.	2006-01	16393463
T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity.	2006-01	16393267
Selective action of fluoroquinolones against intracellular amastigotes of Leishmania (Viannia) panamensis in vitro.	2005-12	16539034
Validation of a novel HPLC sorbent material for the determination of ten quinolones in human and veterinary pharmaceutical formulations.	2005-12	16405173
Preparation and evaluation of sustained ophthalmic gel of enoxacin.	2005-12	16316852
Separation and determination of seven fluoroquinolones by pressurized capillary electrochromatography.	2005-11	16318219
Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit.	2005-10-05	16277734
[Determination of enoxacin in urine by synchronous fluorimetry].	2005-10	16395901
Flow-injection electrogenerated chemiluminescence determination of fluoroquinolones based on its sensitizing effect.	2005-09-01	16134218
Photophysics and photochemistry of nalidixic acid.	2005-08-19	16107187
HPLC determination of enoxacin, ciprofloxacin, norfloxacin and ofloxacin with photoinduced fluorimetric (PIF) detection and multiemission scanning: application to urine and serum.	2005-08-05	16006203
Structure-phototoxicity relationship in Balb/c mice treated with fluoroquinolone derivatives, followed by ultraviolet-A irradiation.	2005-07-04	15917145
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005-06	15962942
Interaction study between enoxacin and fluvoxamine.	2005-06	15905806
Antimicrosporidial activity of (fluoro)quinolones in vitro and in vivo.	2005-05	16004377
Fluoroquinolone-resistant Campylobacter isolates from conventional and antibiotic-free chicken products.	2005-05	15866763
Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.	2005-05	15848290
Vibrational spectroscopic characterization of fluoroquinolones.	2005-05	15820884
Evaluation of phototoxic and photoallergic potentials of 13 compounds by different in vitro and in vivo methods.	2005-04-04	15792876
Determination of fluoroquinolones in edible animal tissue samples by high performance liquid chromatography after solid phase extraction.	2005-04	15881086
Direct determination of five fluoroquinolones in chicken whole blood and in veterinary drugs by HPLC.	2005-03	15792246
Antibacterial studies, DNA oxidative cleavage, and crystal structures of Cu(II) and Co(II) complexes with two quinolone family members, ciprofloxacin and enoxacin.	2005-03	15708788
Induced and photoinduced DNA damage by quinolones: ciprofloxacin, ofloxacin and nalidixic acid determined by comet assay.	2005-02-05	15691228
Celecoxib does not induce convulsions nor does it affect GABAA receptor binding activity in the presence of new quinolones in mice.	2005-01-10	15659296
A novel approach to estimate in vitro antibacterial potency of Chinese medicine using a concentration-killing curve method.	2005	16173540
Spectroscopic properties of various quinolone antibiotics in aqueous-organic solvent mixtures.	2004-12-30	15623343
Validation of HPLC method for determination of six fluoroquinolones: cinoxacin, ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin.	2004-12	15909943
Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux.	2004-11-16	15543082
[Simultaneous determination of quinolones in foods by LC/MS/MS].	2004-10	15678937
Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture.	2004-07-13	15244525
Enoxacin trihydrate.	2004-04	15071236
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.	2004-04	15047530
Sensitivity and spectrum of bacterial isolates in infectious otitis externa.	2004-03	15228846
[The history of the development and changes of quinolone antibacterial agents].	2003	15143768
Enoxacin acute liver injury.	1992-05	1506651
Interaction of the new quinolone antibacterial agent levofloxacin with fenbufen in mice.	1992-03	1622442
Assessment of temafloxacin neurotoxicity in rodents.	1991-12-30	1662895
Hippocampus and frontal cortex are the potential mediatory sites for convulsions induced by new quinolones and non-steroidal anti-inflammatory drugs.	1991-06	1651287

Patents

Sample Use Guides

In Vivo Use Guide

Enoxacin should be taken at least one hour before or at least two hours after a meal. For treatment uncomplicated urethral or cervical gonorrhea: 400 mg single dose. For treatment uncomplicated urinary tract infections 200 mg q12h for 7 days. For treatment complicated urinary tract infections: 400 mg q12h for 14 days. Dosage should be adjusted in patients with a creatinine clearance value of 30 mL/min/1.73 m 2 or less.

Route of Administration: Oral

In Vitro Use Guide

The in vitro antibacterial activity of AT-2266 (Enoxacin ) was tested by the determination of minimal bactericidal concentrations (MBCs) and the reduction of viable cells during exposure to the drug for 24 h. MIC90s of AT-2266 for P. aeruginosa resistant to gentamicin and Enterobacteriaceae resistant to nalidixic acid were 3.13 and 12.5 mkg/ml, respectively

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:59:21 GMT 2025` Edited by `admin` on `Wed Apr 02 09:59:21 GMT 2025`
Record UNII	325OGW249P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PENETREX

Preferred Name

English

ENOXACIN

Official Name

English

NSC-629661

Code

English

Enoxacin [WHO-DD]

Common Name

English

PD 107779

Code

English

1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid

Systematic Name

English

CI-919

Code

English

1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 1-ETHYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)

Common Name

English

AT-2266

Code

English

ENOXACIN [MI]

Common Name

English

1-ETHYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

Systematic Name

English

ENOXACIN [VANDF]

Common Name

English

PD-107779

Code

English

ENOXACIN [USAN]

Common Name

English

NSC-758416

Code

English

ENOXACIN [ORANGE BOOK]

Common Name

English

enoxacin [INN]

Common Name

English

ENOXACIN [MART.]

Common Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/15/1459